Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia

医学 累积发病率 内科学 阿糖胞苷 移植 随机化 造血干细胞移植 随机对照试验 肿瘤科 白血病 外科
作者
Martin Bornhäuser,Christoph Schliemann,Johannes Schetelig,Christoph Röllig,Michael Krämer,Bertram Glaß,Uwe Platzbecker,Andreas Burchert,Mathias Hänel,Lutz Peter Müller,Stefan Klein,Gesine Bug,Dietrich Wilhelm Beelen,Wolf Rösler,Kerstin Schäfer‐Eckart,Christoph Schmid,Edgar Jost,Georg Lenz,Johanna Tischer,Karsten Spiekermann
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:9 (4): 519-519 被引量:56
标识
DOI:10.1001/jamaoncol.2022.7605
摘要

Importance: The ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate. Objective: To explore the optimal therapy for patients with intermediate-risk AML after first complete remission. Design, Settings, and Participants: This investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)-matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021. Interventions: Patients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related). Main Outcomes and Measures: End points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes. Results: A total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P < .001). Nonrelapse mortality at 2 years after primary allogeneic HCT was 9% (95% CI, 5%-19%) and 2% (95% CI, 0%-11%) after consolidation chemotherapy (P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups. Conclusions and Relevance: Primary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor. Trial Registration: ClinicalTrials.gov Identifier: NCT01246752.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
H2发布了新的文献求助10
1秒前
123456完成签到,获得积分10
2秒前
2秒前
RXE关注了科研通微信公众号
3秒前
科研通AI6.2的应助被fortuna采纳,获得10
3秒前
ww完成签到,获得积分10
3秒前
Meng发布了新的文献求助10
3秒前
4秒前
5秒前
SHY完成签到,获得积分20
5秒前
椰汁味完成签到,获得积分10
6秒前
哭泣煎蛋完成签到 ,获得积分10
6秒前
刘柳发布了新的文献求助10
6秒前
脑洞疼的应助被xh采纳,获得10
6秒前
烟花的应助被tph采纳,获得10
6秒前
7秒前
华仔的应助被zero采纳,获得10
7秒前
李健的小迷弟的应助被cc采纳,获得10
7秒前
啊啊发布了新的文献求助80
7秒前
ding的应助被蓝色记忆采纳,获得10
7秒前
sunnymoon发布了新的文献求助10
7秒前
隶书发布了新的文献求助60
8秒前
阿金完成签到,获得积分20
8秒前
8秒前
8秒前
蓝天的应助被秃头的彬彬采纳,获得10
8秒前
BingYu发布了新的文献求助10
8秒前
龙仔的应助被华安采纳,获得10
9秒前
黑就嘿完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
自然黎云完成签到,获得积分20
10秒前
愉快惮的应助被caijiaqi采纳,获得10
10秒前
10秒前
所所的应助被caijiaqi采纳,获得10
10秒前
10秒前
小王同学完成签到,获得积分10
10秒前
10秒前
烂漫的涫完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161554
求助须知:如何正确求助?哪些是违规求助? 9556174
关于积分的说明 21732775
捐赠科研通 7751537
什么是DOI,文献DOI怎么找? 3427556
关于科研通互助平台的介绍 2552588
邀请新用户注册赠送积分活动 2472023